With a record number of FDA biosimilar approvals in 2024, CMOs specializing in biologics can expect to see higher biosimilar volumes, according to GlobalData.
Fujifilm Diosynth Biotechnologies will be known as Fujifilm Biotechnologies, with CDMO services from preclinical to commercialization for biologics, advanced therapies, and vaccines.
The biotech company has selected Sterling Pharma Solutions to produce cGMP-quality material for Phase 1 clinical trials of its antibody-drug conjugate KIVU-107.
